Paul Raphaelian, MD
Retina Specialist · Norton Shores, MINPI 1164450201
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Novartis accounts for 86.1% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for retina specialist clinicians in MI, where the typical reported total is $3,612.
Across 2 payments — averaging $44.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$76
- Genentech USA, Inc.$12
Across 56 payments — averaging $3916.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Apellis Pharmaceuticals, Inc.$219K
What the payments were for
- Food & beverage$89100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 1 | $76 |
| Genentech USA, Inc. | 1 | $12 |
How this compares
$89 in reported general payments places this provider in the 5th percentile of 52 retina specialist providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 141 | $6,857 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 106 | $2,086 |
| Ketorolac Tromethamine | 45 | $1,255 |
| Brimonidine Tartrate | 14 | $1,219 |
| Latanoprost | 124 | $1,186 |
| Timolol Maleate | 57 | $1,042 |
| Atropine Sulfate | 11 | $513 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Norton Shores
- Jeremy WolfeRoyal Oak$809K
- Lisa FaiaRoyal Oak$520K
- Tarek HassanRoyal Oak$460K
- Asheesh TewariDearborn$204K
- Sandeep RandhawaRoyal Oak$94K
- Kimberly DrenserRoyal Oak$79K
- Kanishka JayasunderaAnn Arbor$49K
- Edward KorotGrand Rapids$44K
- Adam WeinerRoyal Oak$31K
- Michael TreseRoyal Oak$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.